I am an enthusiastic and motivated storyteller with six years of experience in market access and behavioral health. Throughout my career,
I have gained a thorough understanding of various rare diseases and complex medical conditions. I actively leverage my real-world experience across different healthcare settings to navigate the complex landscapes of research, clinical trials, FDA approvals, and the insurance challenges encountered in both commercial and Medicare/Medicaid spheres.
Drawing on my experience, I craft narratives illuminating unmet needs within these specialized therapeutic areas, showcasing the innovation and hope that orphan drugs can offer. A strong foundation in storytelling focused on rare diseases allows me to highlight the significant challenges faced across audiences and craft narratives that bring attention to the unmet needs in these niche therapeutic areas, showcasing the innovation and hope that orphan drugs can provide.
I have gained a thorough understanding of various rare diseases and complex medical conditions. I actively leverage my real-world experience across different healthcare settings to navigate the complex landscapes of research, clinical trials, FDA approvals, and the insurance challenges encountered in both commercial and Medicare/Medicaid spheres.
Drawing on my experience, I craft narratives illuminating unmet needs within these specialized therapeutic areas, showcasing the innovation and hope that orphan drugs can offer. A strong foundation in storytelling focused on rare diseases allows me to highlight the significant challenges faced across audiences and craft narratives that bring attention to the unmet needs in these niche therapeutic areas, showcasing the innovation and hope that orphan drugs can provide.
Professional Portfolio
Payer Facing Materials
Unbranded unmet needs presentation for digital therapeutics (DTx) in MDD for use in customer engagements focusing on the unmet needs identified within the MDD treatment landscape and outline the role DTx may be able to play in addressing them.
Streamlined Payer Value Prop: A succinct version of the traditionally long-form value proposition is to communicate with payers that KEVZARA offers a viable treatment option for adult patients with polymyalgia rheumatica (PMR).
Payer Value Propr for Specialty Pharmacies: A communication was created to identify to specialty pharmacy stakeholders the unique value proposition offered by KEVZARA to patients with PMR. Most importantly, the ability for KEVZARA to reduce glucocorticoid burden.
Payer Value Propr for Specialty Pharmacies: A communication was created to identify to specialty pharmacy stakeholders the unique value proposition offered by KEVZARA to patients with PMR. Most importantly, the ability for KEVZARA to reduce glucocorticoid burden.
Patient and HCP Facing Materials
A simple step-by-step guide to assist HCPs/office staff in completing a prior authorization to support more consistent coverage decisions.
This guide outlines the authorization and appeals process for patients prescribed SCEMBLIX. It includes details on understanding prior authorization requirements, the steps involved in the authorization process, handling potential denials, and how to file an appeal.
This patient enrollment brochure was created to provide the latest information on Medicare coverage. The brochure includes enrollment parameters for Medicare patients. In addition, the brochure provides context on recent changes to Medicare coverage that were made based on the Inflation Reduction Act (IRA).